Creative Medical Technology (NASDAQ:CELZ) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Creative Medical Technology (NASDAQ:CELZ) from a hold rating to a sell rating in a report released on Saturday.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Creative Medical Technology in a research report on Monday, December 15th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Reduce”.

Creative Medical Technology Trading Up 0.5%

Shares of CELZ stock opened at $2.12 on Friday. The company’s fifty day moving average price is $2.99 and its 200-day moving average price is $3.00. The stock has a market cap of $5.47 million, a PE ratio of -0.73 and a beta of 2.06. Creative Medical Technology has a 12 month low of $1.69 and a 12 month high of $6.90.

Creative Medical Technology (NASDAQ:CELZ) last issued its quarterly earnings results on Friday, November 7th. The company reported ($0.48) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.48). On average, sell-side analysts forecast that Creative Medical Technology will post -3.19 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Creative Medical Technology

A hedge fund recently bought a new stake in Creative Medical Technology stock. Armistice Capital LLC acquired a new position in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 148,000 shares of the company’s stock, valued at approximately $321,000. Armistice Capital LLC owned about 3.38% of Creative Medical Technology as of its most recent SEC filing. Hedge funds and other institutional investors own 1.42% of the company’s stock.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical?stage biotechnology company focused on the development, manufacture and commercialization of exosome?based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti?inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell?free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.